by Martin Howe
Just days ago, Pfizer and BioNtech announced the success of their phase 3 vaccine trials, with 90% efficacy against Covid-19. The headlines bode well that vaccines will be deployed within the coming months. This will accelerate the path to far fewer infections and a global economic recovery from this pandemic.The cautious words of Professor Ugur Sahin, co-founder and CEO of BioNtech, shouldn’t be ignored though. They simply highlight the uncertainties that are still ahead. “The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent Covid-19, he said, in the announcement. ” Not the definitive statement that we are all longing for. Vaccines are a critical measure in the fight against coronavirus. But ultimately, they are unlikely to be the one-shot panacea on their own. More measures will be needed to keep it under control and to combat against the risks of mutations resistant to vaccines.